2017 State of the Science Symposium Evaluation

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	NA
Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations.	Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations. - 5	Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations. - 4	Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations. - 3	Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations. - 2	Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations. - 1	Examine the current medical evidence and complications associated with the use of therapeutic hypothermia (also called targeted temperature management) for comatose cardiac arrest victims who experienced out-of-hospital ventricular tachycardia and ventricular fibrillations. - NA
Effectively identify the clinical applications of temperature management for neurological patients.	Effectively identify the clinical applications of temperature management for neurological patients. - 5	Effectively identify the clinical applications of temperature management for neurological patients. - 4	Effectively identify the clinical applications of temperature management for neurological patients. - 3	Effectively identify the clinical applications of temperature management for neurological patients. - 2	Effectively identify the clinical applications of temperature management for neurological patients. - 1	Effectively identify the clinical applications of temperature management for neurological patients. - NA
Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill.	Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill. - 5	Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill. - 4	Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill. - 3	Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill. - 2	Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill. - 1	Describe the variation in antibiotic pharmacokinetics and pharmacodynamics in the critically ill. - NA
Apply precision medicine principles to antibiotic regimens in the critically ill.	Apply precision medicine principles to antibiotic regimens in the critically ill. - 5	Apply precision medicine principles to antibiotic regimens in the critically ill. - 4	Apply precision medicine principles to antibiotic regimens in the critically ill. - 3	Apply precision medicine principles to antibiotic regimens in the critically ill. - 2	Apply precision medicine principles to antibiotic regimens in the critically ill. - 1	Apply precision medicine principles to antibiotic regimens in the critically ill. - NA
Develop action plans for dealing with antibiotic optimization in the critically ill.	Develop action plans for dealing with antibiotic optimization in the critically ill. - 5	Develop action plans for dealing with antibiotic optimization in the critically ill. - 4	Develop action plans for dealing with antibiotic optimization in the critically ill. - 3	Develop action plans for dealing with antibiotic optimization in the critically ill. - 2	Develop action plans for dealing with antibiotic optimization in the critically ill. - 1	Develop action plans for dealing with antibiotic optimization in the critically ill. - NA
Differentiate between shared decision making and traditional informed consent.	Differentiate between shared decision making and traditional informed consent. - 5	Differentiate between shared decision making and traditional informed consent. - 4	Differentiate between shared decision making and traditional informed consent. - 3	Differentiate between shared decision making and traditional informed consent. - 2	Differentiate between shared decision making and traditional informed consent. - 1	Differentiate between shared decision making and traditional informed consent. - NA
Implement a shared decision making model that includes strategies to overcome common barriers	Implement a shared decision making model that includes strategies to overcome common barriers - 5	Implement a shared decision making model that includes strategies to overcome common barriers - 4	Implement a shared decision making model that includes strategies to overcome common barriers - 3	Implement a shared decision making model that includes strategies to overcome common barriers - 2	Implement a shared decision making model that includes strategies to overcome common barriers - 1	Implement a shared decision making model that includes strategies to overcome common barriers - NA
Determine when patients are ready for ventilator liberation.	Determine when patients are ready for ventilator liberation. - 5	Determine when patients are ready for ventilator liberation. - 4	Determine when patients are ready for ventilator liberation. - 3	Determine when patients are ready for ventilator liberation. - 2	Determine when patients are ready for ventilator liberation. - 1	Determine when patients are ready for ventilator liberation. - NA
Employ an evidence-based approach to ventilator liberation.	Employ an evidence-based approach to ventilator liberation. - 5	Employ an evidence-based approach to ventilator liberation. - 4	Employ an evidence-based approach to ventilator liberation. - 3	Employ an evidence-based approach to ventilator liberation. - 2	Employ an evidence-based approach to ventilator liberation. - 1	Employ an evidence-based approach to ventilator liberation. - NA
Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula.	Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula. - 5	Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula. - 4	Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula. - 3	Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula. - 2	Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula. - 1	Reduce risk of extubation failure by utilizing evidence-based guidelines for the use of noninvasive ventilation and high flow nasal cannula. - NA
Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU.	Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU. - 5	Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU. - 4	Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU. - 3	Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU. - 2	Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU. - 1	Review the latest survival trends and prognostic factors in critically ill cancer patients admitted to the ICU. - NA
Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients.	Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients. - 5	Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients. - 4	Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients. - 3	Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients. - 2	Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients. - 1	Identify the most common reasons patients with cancer require ICU admission and utilize the most current advances in the management of these critically ill patients. - NA
Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure.	Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure. - 5	Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure. - 4	Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure. - 3	Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure. - 2	Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure. - 1	Utilize evidence based diagnostic and management approaches to the critically ill cancer patients with acute respiratory failure. - NA
Recognize the relationship between critical illness and the human microbiome.	Recognize the relationship between critical illness and the human microbiome. - 5	Recognize the relationship between critical illness and the human microbiome. - 4	Recognize the relationship between critical illness and the human microbiome. - 3	Recognize the relationship between critical illness and the human microbiome. - 2	Recognize the relationship between critical illness and the human microbiome. - 1	Recognize the relationship between critical illness and the human microbiome. - NA
Identify patients whose microbiome is likely to be affected by critical illness.	Identify patients whose microbiome is likely to be affected by critical illness. - 5	Identify patients whose microbiome is likely to be affected by critical illness. - 4	Identify patients whose microbiome is likely to be affected by critical illness. - 3	Identify patients whose microbiome is likely to be affected by critical illness. - 2	Identify patients whose microbiome is likely to be affected by critical illness. - 1	Identify patients whose microbiome is likely to be affected by critical illness. - NA
Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients.	Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients. - 5	Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients. - 4	Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients. - 3	Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients. - 2	Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients. - 1	Apply evidence-based alterative treatment options to maintain the microbiome in the critically ill patients. - NA
Define contraction band necrosis.	Define contraction band necrosis. - 5	Define contraction band necrosis. - 4	Define contraction band necrosis. - 3	Define contraction band necrosis. - 2	Define contraction band necrosis. - 1	Define contraction band necrosis. - NA
Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results.	Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results. - 5	Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results. - 4	Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results. - 3	Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results. - 2	Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results. - 1	Describe the clinical characteristic of neurogenic stunned myocardium in laboratory, echocardiogram and EKG results. - NA
Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy.	Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy. - 5	Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy. - 4	Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy. - 3	Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy. - 2	Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy. - 1	Utilize appropriate treatment algorithms for patients presenting with sever stress cardiomyopathy. - NA
Identify the benefits of precision medicine over “one size fits all” therapy.	Identify the benefits of precision medicine over “one size fits all” therapy. - 5	Identify the benefits of precision medicine over “one size fits all” therapy. - 4	Identify the benefits of precision medicine over “one size fits all” therapy. - 3	Identify the benefits of precision medicine over “one size fits all” therapy. - 2	Identify the benefits of precision medicine over “one size fits all” therapy. - 1	Identify the benefits of precision medicine over “one size fits all” therapy. - NA
Describe how the data rich environment of the ICU may identify patient subsets for research and precision management.	Describe how the data rich environment of the ICU may identify patient subsets for research and precision management. - 5	Describe how the data rich environment of the ICU may identify patient subsets for research and precision management. - 4	Describe how the data rich environment of the ICU may identify patient subsets for research and precision management. - 3	Describe how the data rich environment of the ICU may identify patient subsets for research and precision management. - 2	Describe how the data rich environment of the ICU may identify patient subsets for research and precision management. - 1	Describe how the data rich environment of the ICU may identify patient subsets for research and precision management. - NA
Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure.	Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure. - 5	Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure. - 4	Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure. - 3	Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure. - 2	Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure. - 1	Describe the beneficial effects of high flow nasal cannula and noninvasive ventilation (NIV) in patients with hypoxemia respiratory failure. - NA
Employ an evidence based approach to lung protective ventilation.	Employ an evidence based approach to lung protective ventilation. - 5	Employ an evidence based approach to lung protective ventilation. - 4	Employ an evidence based approach to lung protective ventilation. - 3	Employ an evidence based approach to lung protective ventilation. - 2	Employ an evidence based approach to lung protective ventilation. - 1	Employ an evidence based approach to lung protective ventilation. - NA
Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques.	Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques. - 5	Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques. - 4	Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques. - 3	Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques. - 2	Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques. - 1	Implement evidence-bases strategies for ventilatory support and adjunctive therapies in patients utilizing both pharmacologic and nonpharmacologic techniques. - NA
Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation.	Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation. - 5	Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation. - 4	Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation. - 3	Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation. - 2	Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation. - 1	Identify the major causes of morbidity and mortality of patients undergoing hematopoietic stem cell transplantation. - NA
Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care.	Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care. - 5	Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care. - 4	Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care. - 3	Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care. - 2	Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care. - 1	Describe the unique pulmonary complications patients encounter after stem cell transplantation requiring intensive care. - NA
Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant.	Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant. - 5	Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant. - 4	Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant. - 3	Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant. - 2	Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant. - 1	Implement best practices for management of infection and graft-versus-host disease associated with stem cell transplant. - NA

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1	NA
Targeted Temperature Management: The Future - Kiwon Lee, M.D.	Targeted Temperature Management: The Future - Kiwon Lee, M.D. - 5	Targeted Temperature Management: The Future - Kiwon Lee, M.D. - 4	Targeted Temperature Management: The Future - Kiwon Lee, M.D. - 3	Targeted Temperature Management: The Future - Kiwon Lee, M.D. - 2	Targeted Temperature Management: The Future - Kiwon Lee, M.D. - 1	Targeted Temperature Management: The Future - Kiwon Lee, M.D. - NA
Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM	Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM - 5	Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM - 4	Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM - 3	Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM - 2	Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM - 1	Being Precise With Antibiotics in the Critically Ill - Scott Bolesta, Pharm.D., BCPS, FCCM - NA
An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC	An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC - 5	An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC - 4	An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC - 3	An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC - 2	An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC - 1	An Evidence-Based Approach to Ventilator Liberation - Dean Hess, Ph.D., RRT, FAARC - NA
Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D.	Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D. - 5	Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D. - 4	Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D. - 3	Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D. - 2	Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D. - 1	Advanced Hemodynamic Management for Neurogenic Stunned Myocardium - Kiwon Lee, M.D. - NA
Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM	Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 5	Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 4	Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 3	Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 2	Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 1	Intensive Care of the Cancer Patient: Current and Future Directions - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - NA
Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D.	Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D. - 5	Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D. - 4	Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D. - 3	Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D. - 2	Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D. - 1	Shared Decision Making Way Before the End of Life - Eduardo Martinez-Dubouchet, M.D. - NA
Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM	Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM - 5	Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM - 4	Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM - 3	Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM - 2	Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM - 1	Can Critical Illness and the Microbiome Play Nice Together? - Scott Bolesta, Pharm.D., BCPS, FCCM - NA
An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC	An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC - 5	An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC - 4	An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC - 3	An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC - 2	An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC - 1	An Evidence-Based Approach to Mechanical Ventilation of the Patient With Hypoxemia Respiratory Failure - Dean Hess, Ph.D., RRT, FAARC - NA
Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D.	Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D. - 5	Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D. - 4	Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D. - 3	Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D. - 2	Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D. - 1	Precision Medicine: Why Don’t All Patients Respond the Same Way? - Eduardo Martinez-Dubouchet, M.D. - NA
Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM	Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 5	Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 4	Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 3	Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 2	Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - 1	Complications of Hematopoietic Stem Cell Transplantation Requiring ICU Care - Stephen M. Pastores, M.D., FACP, FCCP, FCCM - NA

Was this course fair, balanced and without commercial bias? *

Yes

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

If you checked "No,” please tell us why: *

If you checked "No,” please explain why you would not recommend this course: *

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

Leave this field blank

You are here

2017 State of the Science Symposium Evaluation